The information on this page is intended for healthcare professionals only.


  • REAL COMMITMENT by Ferring to growth hormone deficiency and ZOMACTON® in the United States
  • DOSING FLEXIBILITY with 5-mg and 10-mg vials available
  • STRONG SUPPORT through the ZoGo Support Program, including a variety of financial assistance programs to meet individual patient needs
  • ENHANCED VALUE with cost-effective, affordable treatment

A needle-free option for patients and caregivers administering ZOMACTON® 5 mg

Available in 5-mg
and 10-mg vials

Also available:

ZOMA-JetTM 5, a needle-free option for patients and caregivers administering ZOMACTON® 5 mg

To learn more about enrolling your patients, call 1-844-944-ZOGO (9646)

ZOOM supports your management of pediatric GHD with ZOMACTON® by providing one-stop access to all ZOMACTON® financial, pre-authorization, patient support, and brand resources while delivering time-saving efficiencies.


ZOMACTON® (somatropin) for Injection is a recombinant human growth hormone (GH) indicated for:
  • Treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous GH.
  • Replacement of endogenous GH in adults with GH deficiency.

Important Safety Information

ZOMACTON® is contraindicated in patients with:
  • Acute critical illness after open heart surgery, abdominal surgery or multiple accidental trauma, or with acute respiratory failure due to the risk of increased mortality.
  • Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to the risk of death.
  • Active malignancy.
  • Hypersensitivity to ZOMACTON®, its excipients, or diluents.
  • Active proliferative or severe non-proliferative diabetic retinopathy.
  • Pediatric patients with closed epiphyses


  • Increased Risk of Neoplasm: An increased risk of a second neoplasm has been reported in childhood cancer survivors. Monitor patients with preexisting tumors for progression or recurrence or have a history of GH deficiency secondary to an intracranial neoplasm.
  • Glucose Intolerance and Diabetes Mellitus: ZOMACTON® may decrease insulin sensitivity, particularly at higher doses. New-onset type 2 diabetes mellitus has been reported. Monitor glucose levels periodically in all patients, especially in patients with existing diabetes mellitus or at risk for development. Doses of antidiabetic agents may require adjustment.
  • Intracranial Hypertension: Intracranial hypertension with papilledema, visual changes, headache, nausea, and/or vomiting have been reported in a small number of patients. Fundoscopic examination should be performed before initiating treatment and periodically. Stop treatment if papilledema occurs.
  • Hypersensitivity: Serious hypersensitivity reactions including anaphylactic reactions and angioedema may occur when using somatropin products. Seek prompt medical attention if an allergic reaction occurs.
  • Fluid Retention: Fluid retention may occur and may be dose-dependent.
  • Hypoadrenalism: Monitor patients for reduced serum cortisol levels and/or need for glucocorticoid dose increases in those with known hypoadrenalism.
  • Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen.
  • Slipped Capital Femoral Epiphysis in Pediatric Patients: Slipped capital femoral epiphysis may occur. Evaluate patients with onset of a limp or hip/knee pain.
  • Progression of Preexisting Scoliosis in Pediatric Patients: Progression of scoliosis can occur. Patients with a history of scoliosis should be monitored.
  • Pancreatitis: Pancreatitis has been reported and should be considered in patients with abdominal pain, especially pediatric patients.
  • Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative: Serious and fatal reactions can occur in neonates and infants treated with benzyl alcohol-preserved drugs, including the diluent for ZOMACTON® 5 mg vial. Reconstitute with normal saline, if administering ZOMACTON® 5 mg vial. Reconstitute with normal saline, if administering ZOMACTON® 5 mg to infants.
  • Lipoatrophy: Injection sites should be rotated to avoid tissue atrophy.


Most common adverse reactions (10% or greater incidence) in adult and pediatric patients include: upper respiratory infection, fever, pharyngitis, headache, otitis media, edema, arthralgia, paresthesia, myalgia, pain, rhinitis, peripheral edema, back pain, flu syndrome, and AST increased.


  • Glucocorticoids: Patients treated with glucocorticoids may require an increased dose.
  • Pharmacologic Glucocorticoid Therapy and Supraphysiologic Glucocorticoid Treatment: Should be carefully adjusted in pediatric patients to avoid hypoadrenalism or an inhibitory effect on growth.
  • Cytochrome P450-Metabolized Drugs: Monitor carefully if used with ZOMACTON® as clearance may be altered.
  • Oral Estrogen: Larger doses of ZOMACTON® may be required.
  • Insulin and/or Other Hypoglycemic Agents: Dose adjustment may be required.


  • Pregnancy and Lactation: If ZOMACTON® 5 mg is needed, reconstitute with normal saline, or use the ZOMACTON® 10 mg benzyl alcohol-free formulation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 800.FDA.1088.

Please see Full Prescribing Information


The individuals depicted are models, not actual patients.